Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

Microenvironmental interactions between endothelial and lymphoma cells: a role for the canonical WNT pathway in Hodgkin lymphoma.

Linke F, Harenberg M, Nietert MM, Zaunig S, von Bonin F, Arlt A, Szczepanowski M, Weich HA, Lutz S, Dullin C, Janovská P, Krafčíková M, Trantírek L, Ovesná P, Klapper W, Beissbarth T, Alves F, Bryja V, Trümper L, Wilting J, Kube D.

Leukemia. 2017 Feb;31(2):361-372. doi: 10.1038/leu.2016.232. Epub 2016 Aug 18.

PMID:
27535218
2.

Integration of CD45-positive leukocytes into newly forming lymphatics of adult mice.

Buttler K, Lohrberg M, Gross G, Weich HA, Wilting J.

Histochem Cell Biol. 2016 Jun;145(6):629-36. doi: 10.1007/s00418-015-1399-y. Epub 2016 Jan 9.

3.

De novo hem- and lymphangiogenesis by endothelial progenitor and mesenchymal stem cells in immunocompetent mice.

Buttler K, Badar M, Seiffart V, Laggies S, Gross G, Wilting J, Weich HA.

Cell Mol Life Sci. 2014 Apr;71(8):1513-27. doi: 10.1007/s00018-013-1460-8. Epub 2013 Sep 1.

PMID:
23995988
4.

VEGFR-3 is expressed on megakaryocyte precursors in the murine bone marrow and plays a regulatory role in megakaryopoiesis.

Thiele W, Krishnan J, Rothley M, Weih D, Plaumann D, Kuch V, Quagliata L, Weich HA, Sleeman JP.

Blood. 2012 Aug 30;120(9):1899-907. doi: 10.1182/blood-2011-09-376657. Epub 2012 Jul 13.

PMID:
22797697
5.

DNA methylation regulates expression of VEGF-R2 (KDR) and VEGF-R3 (FLT4).

Quentmeier H, Eberth S, Romani J, Weich HA, Zaborski M, Drexler HG.

BMC Cancer. 2012 Jan 17;12:19. doi: 10.1186/1471-2407-12-19.

6.

Cortactin deficiency is associated with reduced neutrophil recruitment but increased vascular permeability in vivo.

Schnoor M, Lai FP, Zarbock A, Kläver R, Polaschegg C, Schulte D, Weich HA, Oelkers JM, Rottner K, Vestweber D.

J Exp Med. 2011 Aug 1;208(8):1721-35. doi: 10.1084/jem.20101920. Epub 2011 Jul 25.

7.

Adipose tissue-derived soluble fms-like tyrosine kinase 1 is an obesity-relevant endogenous paracrine adipokine.

Herse F, Fain JN, Janke J, Engeli S, Kuhn C, Frey N, Weich HA, Bergmann A, Kappert K, Karumanchi SA, Luft FC, Muller DN, Staff AC, Dechend R.

Hypertension. 2011 Jul;58(1):37-42. doi: 10.1161/HYPERTENSIONAHA.111.171322. Epub 2011 May 9.

PMID:
21555675
8.

High-resolution mass spectrometric analysis of the secretome from mouse lung endothelial progenitor cells.

Hemmen K, Reinl T, Buttler K, Behler F, Dieken H, Jänsch L, Wilting J, Weich HA.

Angiogenesis. 2011 May;14(2):163-72. doi: 10.1007/s10456-011-9200-x. Epub 2011 Jan 15.

PMID:
21234671
9.

Mouse lung contains endothelial progenitors with high capacity to form blood and lymphatic vessels.

Schniedermann J, Rennecke M, Buttler K, Richter G, Städtler AM, Norgall S, Badar M, Barleon B, May T, Wilting J, Weich HA.

BMC Cell Biol. 2010 Jul 1;11:50. doi: 10.1186/1471-2121-11-50.

10.

Neuroblastoma progression correlates with downregulation of the lymphangiogenesis inhibitor sVEGFR-2.

Becker J, Pavlakovic H, Ludewig F, Wilting F, Weich HA, Albuquerque R, Ambati J, Wilting J.

Clin Cancer Res. 2010 Mar 1;16(5):1431-41. doi: 10.1158/1078-0432.CCR-09-1936. Epub 2010 Feb 23.

11.

Lymphatics and inflammation.

Wilting J, Becker J, Buttler K, Weich HA.

Curr Med Chem. 2009;16(34):4581-92. Review.

PMID:
19903150
12.

Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth.

Albuquerque RJ, Hayashi T, Cho WG, Kleinman ME, Dridi S, Takeda A, Baffi JZ, Yamada K, Kaneko H, Green MG, Chappell J, Wilting J, Weich HA, Yamagami S, Amano S, Mizuki N, Alexander JS, Peterson ML, Brekken RA, Hirashima M, Capoor S, Usui T, Ambati BK, Ambati J.

Nat Med. 2009 Sep;15(9):1023-30. doi: 10.1038/nm.2018. Epub 2009 Aug 9.

13.

Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model.

Bergmann A, Ahmad S, Cudmore M, Gruber AD, Wittschen P, Lindenmaier W, Christofori G, Gross V, Gonzalves ACh, Gröne HJ, Ahmed A, Weich HA.

J Cell Mol Med. 2010 Jun;14(6B):1857-67. doi: 10.1111/j.1582-4934.2009.00820.x. Epub 2009 Jun 16.

14.

Ectopic bone formation after implantation of a slow release system of polylactic acid and rhBMP-2.

Gruber R, Weich HA, Dullin C, Schliephake H.

Clin Oral Implants Res. 2009 Jan;20(1):24-30. doi: 10.1111/j.1600-0501.2008.01613.x.

PMID:
19126104
15.

Embryonic development and malformation of lymphatic vessels.

Wilting J, Buttler K, Rössler J, Norgall S, Schweigerer L, Weich HA, Papoutsi M.

Novartis Found Symp. 2007;283:220-7; discussion 227-9, 238-41.

PMID:
18300425
16.

Mandibular bone repair by implantation of rhBMP-2 in a slow release carrier of polylactic acid--an experimental study in rats.

Schliephake H, Weich HA, Dullin C, Gruber R, Frahse S.

Biomaterials. 2008 Jan;29(1):103-10.

PMID:
17936352
17.

Similarities and differences of human and experimental mouse lymphangiomas.

Kasten P, Schnöink G, Bergmann A, Papoutsi M, Buttler K, Rössler J, Weich HA, Wilting J.

Dev Dyn. 2007 Oct;236(10):2952-61.

18.

Elevated expression of VEGFR-3 in lymphatic endothelial cells from lymphangiomas.

Norgall S, Papoutsi M, Rössler J, Schweigerer L, Wilting J, Weich HA.

BMC Cancer. 2007 Jun 21;7:105.

19.

In vitro characterization of a slow release system of polylactic acid and rhBMP2.

Schliephake H, Weich HA, Schulz J, Gruber R.

J Biomed Mater Res A. 2007 Nov;83(2):455-62.

PMID:
17477390
20.
21.
23.

Endothelial survival factors and spatial completion, but not pericyte coverage of retinal capillaries determine vessel plasticity.

Hoffmann J, Feng Y, vom Hagen F, Hillenbrand A, Lin J, Erber R, Vajkoczy P, Gourzoulidou E, Waldmann H, Giannis A, Wolburg H, Shani M, Jaeger V, Weich HA, Preissner KT, Hoffmann S, Deutsch U, Hammes HP.

FASEB J. 2005 Dec;19(14):2035-6. Epub 2005 Oct 7.

PMID:
16215210
24.
25.

Vascular endothelial growth factor and its soluble receptor, Flt-1, are not correlated to erythropoietin in diabetics with normal or reduced renal function.

Lenz T, Gauer S, Weich HA, Haak T, Bergner R, Gossmann J.

Nephrology (Carlton). 2005 Feb;10(1):84-9.

PMID:
15705187
26.

Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer.

Bando H, Weich HA, Brokelmann M, Horiguchi S, Funata N, Ogawa T, Toi M.

Br J Cancer. 2005 Feb 14;92(3):553-61.

27.

Increased levels of the soluble variant of the vascular endothelial growth factor receptor VEGFR-1 are associated with a poor prognosis in wound healing.

Eming SA, Lauer G, Cole M, Jurk S, Christ H, Hornig C, Krieg T, Weich HA.

J Invest Dermatol. 2004 Oct;123(4):799-802. No abstract available.

28.

Immunodetection and quantification of vascular endothelial growth factor receptor-3 in human malignant tumor tissues.

Bando H, Brokelmann M, Toi M, Alitalo K, Sleeman JP, Sipos B, Gröne HJ, Weich HA.

Int J Cancer. 2004 Aug 20;111(2):184-91.

29.

An engineered heparin-binding form of VEGF-E (hbVEGF-E). Biological effects in vitro and mobilizatiion of precursor cells.

Heil M, Mitnacht-Krauss R, Issbrücker K, van den Heuvel J, Dehio C, Schaper W, Clauss M, Weich HA.

Angiogenesis. 2003;6(3):201-11.

PMID:
15041796
30.

Quantification of vascular endothelial growth factor-C (VEGF-C) by a novel ELISA.

Weich HA, Bando H, Brokelmann M, Baumann P, Toi M, Barleon B, Alitalo K, Sipos B, Sleeman J.

J Immunol Methods. 2004 Feb 15;285(2):145-55.

PMID:
14980429
31.

Soluble VEGF receptors.

Hornig C, Weich HA.

Angiogenesis. 1999;3(1):33-9.

PMID:
14517442
32.
33.

Expression of vascular endothelial growth factor receptors 1, 2, and 3 in quiescent endothelia.

Witmer AN, Dai J, Weich HA, Vrensen GF, Schlingemann RO.

J Histochem Cytochem. 2002 Jun;50(6):767-77.

PMID:
12019293
34.

Altered expression patterns of VEGF receptors in human diabetic retina and in experimental VEGF-induced retinopathy in monkey.

Witmer AN, Blaauwgeers HG, Weich HA, Alitalo K, Vrensen GF, Schlingemann RO.

Invest Ophthalmol Vis Sci. 2002 Mar;43(3):849-57.

PMID:
11867607
35.

Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer.

Toi M, Bando H, Ogawa T, Muta M, Hornig C, Weich HA.

Int J Cancer. 2002 Mar 1;98(1):14-8.

36.

Renaturation and purification of bone morphogenetic protein-2 produced as inclusion bodies in high-cell-density cultures of recombinant Escherichia coli.

Vallejo LF, Brokelmann M, Marten S, Trappe S, Cabrera-Crespo J, Hoffmann A, Gross G, Weich HA, Rinas U.

J Biotechnol. 2002 Mar 28;94(2):185-94.

PMID:
11796171
37.

Involvement of VEGFR-2 (kdr/flk-1) but not VEGFR-1 (flt-1) in VEGF-A and VEGF-C-induced tube formation by human microvascular endothelial cells in fibrin matrices in vitro.

Koolwijk P, Peters E, van der Vecht B, Hornig C, Weich HA, Alitalo K, Hicklin DJ, Wu Y, Witte L, van Hinsbergh VW.

Angiogenesis. 2001;4(1):53-60.

PMID:
11824379
38.

Perspectives in the biological function, the technical and therapeutic application of bone morphogenetic proteins.

Hoffmann A, Weich HA, Gross G, Hillmann G.

Appl Microbiol Biotechnol. 2001 Oct;57(3):294-308. Review.

PMID:
11759676
39.

Characterization of (123)I-vascular endothelial growth factor-binding sites expressed on human tumour cells: possible implication for tumour scintigraphy.

Li S, Peck-Radosavljevic M, Koller E, Koller F, Kaserer K, Kreil A, Kapiotis S, Hamwi A, Weich HA, Valent P, Angelberger P, Dudczak R, Virgolini I.

Int J Cancer. 2001 Mar 15;91(6):789-96.

40.

VEGF/Flk-1 interaction, a requirement for malignant ascites recurrence.

Stoelcker B, Echtenacher B, Weich HA, Sztajer H, Hicklin DJ, Männel DN.

J Interferon Cytokine Res. 2000 May;20(5):511-7.

PMID:
10841080
41.

Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids.

Hornig C, Barleon B, Ahmad S, Vuorela P, Ahmed A, Weich HA.

Lab Invest. 2000 Apr;80(4):443-54.

PMID:
10780661
42.

Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor.

Monsky WL, Fukumura D, Gohongi T, Ancukiewcz M, Weich HA, Torchilin VP, Yuan F, Jain RK.

Cancer Res. 1999 Aug 15;59(16):4129-35.

43.

Expression and localization of placenta growth factor and PlGF receptors in human meningiomas.

Donnini S, Machein MR, Plate KH, Weich HA.

J Pathol. 1999 Sep;189(1):66-71.

PMID:
10451490
44.

Endothelial growth factor receptors in human fetal heart.

Partanen TA, Makinen T, Arola J, Suda T, Weich HA, Alitalo K.

Circulation. 1999 Aug 10;100(6):583-6.

PMID:
10441093
45.

Detection and quantification of complexed and free soluble human vascular endothelial growth factor receptor-1 (sVEGFR-1) by ELISA.

Hornig C, Behn T, Bartsch W, Yayon A, Weich HA.

J Immunol Methods. 1999 Jun 24;226(1-2):169-77.

PMID:
10410982
46.
47.

Differential binding characteristics and cellular inhibition by soluble VEGF receptors 1 and 2.

Roeckl W, Hecht D, Sztajer H, Waltenberger J, Yayon A, Weich HA.

Exp Cell Res. 1998 May 25;241(1):161-70.

PMID:
9633524
48.

Receptors of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in fetal and adult human kidney: localization and [125I]VEGF binding sites.

Simon M, Röckl W, Hornig C, Gröne EF, Theis H, Weich HA, Fuchs E, Yayon A, Gröne HJ.

J Am Soc Nephrol. 1998 Jun;9(6):1032-44.

49.

Secretion of vascular endothelial growth factor/vascular permeability factor from human luteinized granulosa cells is human chorionic gonadotrophin dependent.

Neulen J, Raczek S, Pogorzelski M, Grunwald K, Yeo TK, Dvorak HF, Weich HA, Breckwoldt M.

Mol Hum Reprod. 1998 Mar;4(3):203-6.

PMID:
9570265
50.

Effects of vascular endothelial growth factor (VEGF)/vascular permeability factor (VPF) on haemodynamics and permselectivity of the isolated perfused rat kidney.

Klanke B, Simon M, Röckl W, Weich HA, Stolte H, Gröne HJ.

Nephrol Dial Transplant. 1998 Apr;13(4):875-85.

PMID:
9568844

Supplemental Content

Loading ...
Support Center